Voyager Therapeutics Operating Income 2014-2022 | VYGR
Voyager Therapeutics operating income from 2014 to 2022. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Voyager Therapeutics Annual Operating Income
(Millions of US $) |
| 2021 |
$-74 |
| 2020 |
$27 |
| 2019 |
$-52 |
| 2018 |
$-91 |
| 2017 |
$-72 |
| 2016 |
$-41 |
| 2015 |
$-20 |
| 2014 |
$-14 |
| 2013 |
$-4 |
Voyager Therapeutics Quarterly Operating Income
(Millions of US $) |
| 2022-03-31 |
$-21 |
| 2021-12-31 |
$6 |
| 2021-09-30 |
$-25 |
| 2021-06-30 |
$-29 |
| 2021-03-31 |
$-26 |
| 2020-12-31 |
$-24 |
| 2020-09-30 |
$85 |
| 2020-06-30 |
$-9 |
| 2020-03-31 |
$-24 |
| 2019-12-31 |
$-14 |
| 2019-09-30 |
$-18 |
| 2019-06-30 |
$9 |
| 2019-03-31 |
$-29 |
| 2018-12-31 |
$-23 |
| 2018-09-30 |
$-21 |
| 2018-06-30 |
$-26 |
| 2018-03-31 |
$-21 |
| 2017-12-31 |
$-12 |
| 2017-09-30 |
$-23 |
| 2017-06-30 |
$-19 |
| 2017-03-31 |
$-18 |
| 2016-12-31 |
$-14 |
| 2016-09-30 |
$-10 |
| 2016-06-30 |
$-10 |
| 2016-03-31 |
$-7 |
| 2015-12-31 |
$-7 |
| 2015-09-30 |
$-4 |
| 2015-06-30 |
$-4 |
| 2015-03-31 |
$-5 |
| 2014-12-31 |
|
| 2014-09-30 |
$-4 |
| 2014-06-30 |
|
| 2014-03-31 |
|
| 2013-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.234B |
$0.037B |
|
Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
|
